We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNN icon
76
Smith & Nephew
SNN
$13.3B
$7M 0.29%
160,734
-24,744
-13% -$1.02M
PVLA
77
Palvella Therapeutics
PVLA
$1.99B
$6.81M 0.28%
18,116
-7,976
-31% -$2.38M
VTR icon
78
Ventas
VTR
$48B
$6.73M 0.27%
98,496
– –
LTC
79
LTC Properties
LTC
$2.06B
$6.64M 0.27%
145,421
– –
CHRS icon
80
Coherus Oncology
CHRS
$217M
$6.44M 0.26%
291,419
-23,743
-8% -$412K
RMD icon
81
ResMed
RMD
$30.6B
$6.36M 0.26%
52,110
-16,864
-24% -$1.87M
PTCT icon
82
PTC Therapeutics
PTCT
$5.64B
$6.28M 0.26%
139,608
+70,956
+103% +$2.8M
LKFT
83
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$6.26M 0.26%
48,525
– –
ACHC icon
84
Acadia Healthcare
ACHC
$2.76B
$6.05M 0.25%
173,155
– –
ZGNX
85
DELISTED
Zogenix, Inc.
ZGNX
$5.93M 0.24%
124,148
+34,386
+38% +$1.38M
LH icon
86
Labcorp
LH
$25.4B
$5.43M 0.22%
36,578
-16,567
-31% -$2.31M
IMMU
87
DELISTED
Immunomedics Inc
IMMU
$5.4M 0.22%
389,313
+101,626
+35% +$1.53M
DOC
88
DELISTED
PHYSICIANS REALTY TRUST
DOC
$5.3M 0.22%
303,908
– –
WCG
89
DELISTED
Wellcare Health Plans, Inc.
WCG
$5.1M 0.21%
17,886
-1,400
-7% -$386K
LGND icon
90
Ligand Pharmaceuticals
LGND
$5.76B
$5.03M 0.21%
70,620
+22,698
+47% +$1.67M
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$5.01M 0.2%
399,604
+110,200
+38% +$1.42M
IOVA icon
92
Iovance Biotherapeutics
IOVA
$1.82B
$4.88M 0.2%
199,073
-17,835
-8% -$269K
TECH icon
93
Bio-Techne
TECH
$11.2B
$4.52M 0.18%
86,804
– –
ALKS icon
94
Alkermes
ALKS
$8.22B
$4.46M 0.18%
198,048
– –
STE icon
95
Steris
STE
$22.3B
$4.32M 0.18%
28,981
-19,022
-40% -$2.54M
ICPT
96
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.29M 0.17%
53,857
-5,418
-9% -$485K
ACAD icon
97
Acadia Pharmaceuticals
ACAD
$4.43B
$4.28M 0.17%
160,147
+55,433
+53% +$1.42M
BHC icon
98
Bausch Health
BHC
$2.57B
$4.26M 0.17%
168,812
– –
UTHR icon
99
United Therapeutics
UTHR
$25.8B
$4.22M 0.17%
54,094
+12,833
+31% +$1.2M
ANAB icon
100
AnaptysBio
ANAB
$1.58B
$4.22M 0.17%
74,798
+8,953
+14% +$645K
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.